Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Pediatrics|June 18, 2016
Improved Behavior and Neuropsychological Function in Children With ROHHAD After High-Dose CyclophosphamideLisa A Jacobson, Shruti Rane, Lisa J McReynolds, et al.
Scientific Reports|June 21, 2023
Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumabRaquel Valls, Jonathan Wagg, Ido Paz-Priel, et al.
Cancer Letters|March 13, 2016
C/EBPβ regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusionDavid J Barakat, Janet Mendonca, Theresa Barberi, et al.
Pediatric Blood & Cancer|February 14, 2014
Patterns of failure after involved field radiation therapy for pediatric and young adult Hodgkin lymphomaMinh-Phuong Huynh-Le, Amanda J Walker, Scott Duke Kominers, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 29, 2022
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 studyAnna Kiialainen, Markus Niggli, Christine L Kempton, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 28, 2021
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitorsChristine Kempton, Peter Trask, Aric Parnes, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 4, 2021
Low immunogenicity of emicizumab in persons with haemophilia AChristophe Schmitt, Thomas Emrich, Sammy Chebon, et al.
Current Medical Research and Opinion|July 30, 2019
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trialAdriana Reyes, Cédric Révil, Markus Niggli, et al.
Molecular Cancer Research : MCR|October 29, 2005
CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50Ido Paz-Priel, Dong Hong Cai, Dehua Wang, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 25, 2021
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studiesMark W Skinner, Claude Négrier, Ido Paz-Priel, et al.
Pageof 3